期刊文献+

一株乳酸乳球菌产γ-氨基丁酸能力及其安全性评价 被引量:12

γ-aminobutyric acid-producing ability and safety evaluation of Lactococcus lactis
下载PDF
导出
摘要 探讨了乳酸乳球菌乳亚种HUCM 201产γ-氨基丁酸的能力,并初步评价了其安全性。以γ-氨基丁酸含量为评价指标,通过正交试验优化了乳酸乳球菌乳亚种HUCM 201菌株产γ-氨基丁酸的发酵条件,即接种量为4%、初始pH值6.5,发酵温度31℃,发酵时间60 h,其发酵液中γ-氨基丁酸的质量浓度可达218.7μg/mL。通过硝基还原酶活性检测、生物胺产生能力分析、吲哚试验和溶血性试验,初步评价了菌株HUCM 201的安全性,发现其硝基还原酶阴性,吲哚试验阴性,无溶血,不能产生酪胺、组胺、尸胺和腐胺生物胺类物质,可初步认为是一株安全的益生菌。 The γ-aminobutyric acid-producing ability of Lactococcus lactis subsp, lactis HUCM 201 was discussed and the strain safety was prelimi-narily evaluated. Using γ-aminobutyric acid concentration as evaluation index, the optimal fermentation condition of strain HUCM 201 was evaluated by orthogonal experiments. The optimal fermentation condition was inoculum 4%, initial pH 6.5, fermentation temperature 31℃ and time 60 h. The γ-aminobutyric acid concentration was determined as 218.7μg/ml based on the optimal fermentation condition. Moreover, the safety of L. lactis subsp. lactis HUCM 201 was evaluated via nitroreductase activity determination, biogenic amines production analysis, indole experiments and haemolysis experiments. The results suggested that the strain HUCM 201 was a nitroreductase-negative, indole-negative, haemolysis-negative bacterium, and could not produce biogenic amines, such as tyramine, histamine, cadaverine, and putrescine. Thus, L. lactis subsp, lactis HUCM 201 was preliminarily considered as safe probiotic bacterium.
作者 孟丹 王丽群 谢国梁 刘晓艳 于纯淼 国立东 MENG Dan WANG Liqun XIE Guoliang LIU Xiaoyan YU Chunmiao GUO Lidong(College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China Food Processing Institute, Heilongjiang Academy o~Agricultural Sciences, Harbin 150086, China)
出处 《中国酿造》 CAS 北大核心 2017年第4期72-77,共6页 China Brewing
基金 黑龙江省自然科学基金项目(C2016052) 黑龙江省教育厅面上项目(12531631) 黑龙江中医药大学校科研基金项目(201104)
关键词 乳酸菌 Γ-氨基丁酸 生物胺 安全性 lactic acid bacteria γ-aminobutyric acid biogenic amine safety
  • 相关文献

参考文献4

二级参考文献69

  • 1国立东,王欣,杜鹏,赵蕊,霍贵成.传统乳制品中乳酸菌的分离及性能研究[J].食品科学,2006,27(3):60-64. 被引量:21
  • 2Liu J. R.,Wang S. Y., Lin Y. Y., Lin C. W. Antitumor Activity of Milk Kefir and Soy Milk Kefir in Tumor-Bearing Mice [J]. Nutr. Cancer,2002,44(2): 182-187.
  • 3Liu J. R.,Chen M. J., Lin C. W. Antimutagenic and Antioxidant Properties of Milk-Kefir and Soymilk-Kefir [J]. J. Agric. Food Chem. 2005,53: 2467-2474.
  • 4G ti yen A.,G tl ven A., G tl lmez M. The effect of kefir on the activities of GSH-Px,GST,CAT,GSHand LPOlevelsincarbontetraehloride-induc edmicetissues [J]. J. Vet. Med. B 2003,50,412-416.
  • 5Lee M. Y., Ahn K. S., Kwon O. K., et al. Anti-inflammatory and anti-allergic effects of kefir in a mouse asthma model [J]. lmmunobiol., 2007,212: 647-654.
  • 6Quir 6 s A., Hem 6 ndez-Ledesma B., Ramos M., et al. Angiotensin -converting enzyme inhibitory activity of peptides derived from eaprine kefir [J]. J. Dairy Sci., 2005,88: 3480-3487.
  • 7Liu J. R., Wang S. Y., Chen M. J. et al. Hypocholesterolaemie effects of milk-kefir and soyamilk-kefir in cholesterol-fed hamsters [J]. Br. J. Nutr., 2006,95: 939-946.
  • 8Vinderola C. G., Duarte J., Thangavel D., et al. Immunomodulating capacity of kefir [J]. J. Dairy Res. 2005,72: 195-202.
  • 9Dobson A.,O'Sullivan O.,Cotter P. D.,et al. High-throughput sequence-based analysis of the bacterial composition of kefir and an associated kefir grain [J]. FEMS Microbiol. Left.,2011,320: 56-62.
  • 10Gulitz A., Stadie J., Ehrmann M. A., et al. Comparative phylobiomic analysis of the bacterial community of water kefir by 16S rRNA gene amplicon sequencing and ARDRA analysis [J]. J Appl. Microbiol., 2013,114(4): 1082-1091.

共引文献20

同被引文献149

引证文献12

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部